Daily Temozolomide for Glioblastoma

(TEMPO Trial)

This trial tests a new method of administering Temozolomide, a chemotherapy drug, for treating glioblastoma, a fast-growing brain cancer. The researchers aim to determine if altering the drug's timing benefits patients when the usual treatment is unlikely to be effective due to a specific tumor marker. Suitable participants have recently diagnosed glioblastoma, have completed a round of radiation and chemotherapy, and have a tumor with an "unmethylated MGMT" marker, indicating that standard chemotherapy might not be effective. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants, offering a chance to benefit from innovative therapy.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

A previous study found that temozolomide, a common treatment for glioblastoma, is generally safe, though it can cause some side effects, often affecting blood health. Despite this, many patients tolerate the drug well. Another study showed that using temozolomide for longer periods does not significantly increase survival, but the side effects remained manageable. Different research noted that the most serious outcomes included hospitalization and severe side effects, which are common with cancer treatments. Overall, the safety of temozolomide is well-understood and acceptable, especially given its long history of use in treating glioblastoma.¹²³⁴⁵

Temozolomide is unique because it is being tested for daily use in treating glioblastoma, a brain cancer that currently uses this drug in combination with radiation in cycles. This approach could potentially enhance its effectiveness by maintaining consistent drug levels in the body, thereby providing continuous pressure on cancer cells. Researchers are excited about this treatment because it offers a novel dosing strategy that might improve patient outcomes compared to the intermittent dosing schedules typically used today.

Research has shown that Temozolomide (TMZ) can extend survival and slow tumor growth in people with glioblastoma, a fast-growing brain cancer. Studies have found that longer treatment with TMZ can increase survival time and delay cancer progression. However, the cancer can sometimes become resistant, ceasing to respond to the treatment. Some research suggests that altering the administration of TMZ might yield better results than the standard approach. While TMZ shows promise, resistance remains a challenge, particularly for those with specific tumor characteristics.⁴⁵⁶⁷⁸